Research programme: bi-specific antibody therapeutics - Zymeworks/Merck & Co

Drug Profile

Research programme: bi-specific antibody therapeutics - Zymeworks/Merck & Co

Alternative Names: Azymetric scaffold

Latest Information Update: 11 Dec 2014

Price : $50

At a glance

  • Originator Zymeworks
  • Developer Merck & Co; Zymeworks
  • Class Bispecific antibodies; Recombinant proteins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Cancer

Most Recent Events

  • 09 Dec 2014 Zymeworks and Merck extend and expand their bi-specific antibody therapeutics collaboration
  • 16 Apr 2013 Preclinical development is ongoing in Canada
  • 30 Aug 2011 Preclinical trials in Cancer in Canada (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top